Amedisys, Inc.(AMED) Stock Research - Grey Stern Research

Amedisys, Inc. (AMED) Stock Analysis

$97.21 (0.06%)

AMED Financial Performance


Use the table below to view Amedisys, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $97.15 -
52 Week Low $89.55 -
52 Week High $98.95 -
Market Cap $3.2 Billion 7/11
Gross Margin 22% 5/11
Profit Margin 5% 6/11
EBITDA margin 12% 6/11
Q2 - 2024 Revenue $591.2 Million 7/11
Q2 - 2024 Earnings $32.3 Million 6/11
Q2 - 2024 Free Cash Flow $50.7 Million 3/11
Trailing 4 Quarters Revenue $2.3 Billion 7/11
Trailing 4 Quarters Earnings $112.0 Million 5/11
Quarterly Earnings Growth 140% 1/11
Annual Earnings Growth 2569% 1/11
Quarterly Revenue Growth 7% 10/11
Annual Revenue Growth 3% 10/11
Cash On Hand $157.4 Million 5/11
Short Term Debt $64.2 Million 5/11
Long Term Debt $351.4 Million 6/11

Amedisys, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Amedisys, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 28.39 5/11
PS 1.39 7/11
PB 2.70 6/11
PC 20.21 6/11
Liabilities to Equity 0.83 9/11
ROA 0.05 5/11
ROE 0.10 6/11
Current Ratio 2.26 3/11
Quick Ratio 0.17 6/11
Long Term Debt to Equity 0.31 8/11
Debt to Equity 0.42 8/11
Burn Rate -71.70 11/11
Cash to Cap 0.05 5/11
CCR 1.57 1/11
EV to EBITDA 49.64 8/11
EV to Revenue 1.53 7/11

Company Details

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

CEO: Mr. Paul Kusserow

Website: https://www.amedisys.com

Address: 3854 American Way Ste A Baton Rouge, LOUISIANA

Exchange: NASDAQ Global Select

Industry: Medical Care Facilities

Amedisys, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Amedisys, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Healthcare Services Group, Inc. HCSG $866.7 Million
Universal Health Services, Inc. UHS $14.1 Billion
Acadia Healthcare Company, Inc. ACHC $7.2 Billion
Surgery Partners, Inc. SGRY $4.2 Billion
Encompass Health Corporation EHC $9.3 Billion
Addus HomeCare Corporation ADUS $2.4 Billion
The Ensign Group, Inc. ENSG $8.7 Billion
Option Care Health, Inc. OPCH $5.4 Billion
The Pennant Group, Inc. PNTG $1.1 Billion
InnovAge Holding Corp. INNV $827.3 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
AMED Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 591.2 Million $32.3 Million
Q1 2024 $ 571.4 Million $14.4 Million
Q4 2023 $ 570.8 Million $39.4 Million
Q3 2023 $ 556.2 Million $26.0 Million
Q2 2023 $ 553.0 Million -$80.3 Million
Q1 2023 $ 556.4 Million $25.2 Million
Q4 2022 $ 562.1 Million $31.7 Million
Q3 2022 $ 558.0 Million $25.6 Million

View All

AMED Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $157.4 Million $2.1 Billion $474.6 Million $1.2 Billion
Q1 2024 $120.7 Million $2.1 Billion $481.8 Million $1.1 Billion
Q4 2023 $126.5 Million $2.1 Billion $488.6 Million $1.1 Billion
Q3 2023 $78.1 Million $2.0 Billion $490.2 Million $1.0 Billion
Q2 2023 $95.4 Million $2.0 Billion $486.8 Million $1.0 Billion
Q1 2023 $49.4 Million $1.9 Billion $485.4 Million $1.1 Billion
Q4 2022 $40.5 Million $2.0 Billion $537.9 Million $1.1 Billion
Q3 2022 $18.0 Million $2.0 Billion $575.8 Million $1.1 Billion

View All

AMED Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $50.7 Million -$1.6 Million $36.7 Million
Q1 2024 -$9.4 Million -$2.9 Million -$25.2 Million
Q4 2023 $58.4 Million -$1.9 Million $44.8 Million
Q3 2023 -$11.0 Million -$1.2 Million -$17.1 Million
Q2 2023 $52.9 Million -$7.9 Million $42.1 Million
Q1 2023 $24.4 Million -$1.6 Million $15.0 Million
Q4 2022 $38.9 Million -$2.0 Million $22.7 Million
Q3 2022 -$15.3 Million -$1.6 Million -$17.3 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions